The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
Abstract
Purpose: Maintenance therapy is associated with improved survival in patients with non–small-cell lung cancer (NSCLC), but few studies have compared active agents in this setting. AVAPERL evaluated the safety and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment. Patients and Methods: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m 2, and pemetrexed 500 mg/m 2 once every 3 weeks for four cycles. Those achieving response or stable disease were randomly assigned at a ratio of 1:1 to maintenance bevacizumab 7.5 mg/kg or bevacizumab 7.5 mg/kg plus pemetrexed 500 mg/m 2 once every 3 weeks until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS) after random assignment. Results: In total, 376 patients received induction treatment, 71.9% achieved disease control, and 67.3% were randomly assigned to maintenance therapy, with 125 and 128 receiving single-agent bevacizumab and bevacizumab plus pemetrexed treatment, respectively. At a median follow-up of 8.1 months, PFS from random assignment was significantly improved in the bevacizumab plus pemetrexed arm (median, 3.7 v 7.4 months; hazard ratio, 0.48; 95% CI, 0.35 to 0.66; P < .001) per a stratified model. The PFS benefit extended across age, performance status, smoking history, and induction response (stable disease v partial response) subgroups. Any grade, grade ≥ 3, and serious adverse events occurred more often with bevacizumab plus pemetrexed maintenance. No new safety signals were observed. Conclusion: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. The combination was well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the time of study publication, OS had not yet been reached.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [33]
In the citing paper
“A second trial33 compared maintenance pemetrexed plus bevacizumab with bevacizumab alone (after first-line induction with bevacizumab, cisplatin, and pemetrexed). The study met its primary end point of statistically significantly longer PFS with bevacizumab plus pemetrexed (7.4 v 3.7 months; hazard ratio [HR], 0.48; 95% CI, 0.35 to 0.66; P < .001).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [33]
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V. A., Hirsh, V., Leighl, N. B., Mezger, J. M., Archer, V. R., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,501
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Self-citationWong, D. W., Leung, E. L., So, K. K., Tam, I. Y. S., Sihoe, A. D., Cheng, L., Ho, K., Au, J. S. K., Chung, L., & Wong, M. P. (2009) · Cancer · doi:10.1002/cncr.24181 · Cited by 726
Research works printed but not linked: 4
- Shih C, 1997, Cancer Res, 57, 1116
- Rittmeyer A, Presented at the European Multidisciplinary Cancer Congress
- Ahn M, Presented at the European Multidisciplinary Cancer Congress
- De Marinis F, Presented at the European Multidisciplinary Cancer Congress
Cited by
Sorted by citations
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K. M., & Felip, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds226 · Cited by 940
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Metadata
- Authors
- Barlesi, F., Scherpereel, A., Rittmeyer, A., Pazzola, A., Ferrer Tur, N., Kim, J.-H., Ahn, M.-J., Aerts, J. G. J. V., Gorbunova, V., Vikström, A., Wong, E. K., Perez-Moreno, P., Mitchell, L., & Groen, H. J. M.
- Affiliations
- Fabrice Barlesi, Aix Marseille University–Assistance Publique Hôpitaux de Marseille and Centre d'Investigation Clinique, Marseille; Arnaud Scherpereel, Hôpital Calmette, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Achim Rittmeyer, Lungenfachklinik Immenhausen, Immenhausen, Germany; Antonio Pazzola, Ospedale Civile Santissima, Annunziata, Sassari, Italy; Neus Ferrer Tur, Hospital Son Llàtzer, Palma de Majorca, Spain; Joo-Hang Kim, Yonsei University College of Medicine; Myung-Ju Ahn,...
- Aix-Marseille Université (FR)
- F. Hoffmann-La Roche AG (CH)
- University of Groningen (NL)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2013-08-20
- Volume
- 31
- Issue
- 24
- Pages
- 3004-3011
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2122798232
- Cited by
- 323
- References
- 29
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 15 · 2023: 7 · 2022: 14 · 2021: 16 · 2020: 22 · 2019: 33 · 2018: 25 · 2017: 29 · 2016: 39 · 2015: 44 · 2014: 44 · 2013: 22
- FWCI
- 40.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- bevacizumab, pemetrexed, maintenance therapy, non-squamous non-small cell lung cancer, cisplatin, progression-free survival, anti-angiogenic therapy, adverse events, subgroup analysis, smoking history, performance status, age, stable disease, partial response
- MeSH terms
- Bevacizumab, Pemetrexed, Adult, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Drug Administration Schedule, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Young Adult, Induction Chemotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
